Explore 3 Stock Ideas & Industry Insights Download Free Report

Envoy Medical Inc.

US COCHW

0.0306USD
-0.0169(35.58%)

Last update at 2026-06-22T19:56:00Z

Day Range

0.030.05
LowHigh

52 Week Range

0.030.09
LowHigh

Fundamentals

  • Previous Close 0.05
  • Market Cap0.00000M
  • Volume41479
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-21.77800M
  • Revenue TTM0.24M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM -0.44300M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -23.75600M -20.79500M -29.90800M -15.92300M -8.67500M
Minority interest - - - - -
Net income -23.75600M -20.79500M -29.90800M -15.92300M -8.67500M
Selling general administrative 7.93M 6.83M 7.28M 3.47M 2.47M
Selling and marketing expenses 1.22M 1.73M 1.67M 0.89M -
Gross profit -0.63300M -0.51700M -0.60600M -0.72000M -0.45900M
Reconciled depreciation 0.30M 0.17M 0.11M 0.07M 0.07M
Ebit -22.27000M -19.97900M -18.37100M -8.70600M -6.87100M
Ebitda -21.96800M -19.80600M -18.23800M -8.63100M -6.80000M
Depreciation and amortization 0.30M 0.17M 0.13M 0.07M 0.07M
Non operating income net other - - - - -
Operating income -22.27000M -19.25600M -18.37100M -8.70600M -6.87100M
Other operating expenses 22.51M 19.48M 18.69M 8.94M 7.18M
Interest expense 1.59M 0.82M - - -
Tax provision - - - - -
Interest income - - - - -
Net interest income -1.59000M -0.81600M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.24M 0.23M 0.32M 0.24M 0.31M
Total operating expenses 21.64M 18.74M 17.77M 7.99M 6.41M
Cost of revenue 0.87M 0.74M 0.92M 0.96M 0.77M
Total other income expense net -1.48600M -1.53900M -11.53700M -7.21700M -1.80400M
Discontinued operations - - - - -
Net income from continuing ops -23.75600M -20.79500M -36.50400M -15.92300M -8.67500M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 8.56M 11.54M 7.64M 2.56M 2.62M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.96M 1.38M 0.96M - -
Total liab 20.32M 30.38M 9.40M 58.72M 47.58M
Total stockholder equity -11.76700M -18.84200M -1.76200M -56.16800M -44.96000M
Deferred long term liab - - - - -
Other current liab 8.47M 5.74M 4.92M 0.34M 0.25M
Common stock 0.00300M 0.00200M 0.00200M - -
Capital stock 0.00300M 0.00200M - 1.39M 1.39M
Retained earnings -313.39600M -284.73400M -257.24200M -225.98500M -210.06200M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M - -
Cash 3.74M 5.48M 4.22M 0.18M 1.12M
Cash and equivalents - - - - -
Total current liabilities 11.56M 7.54M 6.64M 2.52M 1.38M
Current deferred revenue - - - - -
Net debt -2.82000M 14.18M -3.65600M 33.66M 22.36M
Short term debt 0.17M 0.14M 0.16M - -
Short long term debt - - - 0.45M -
Short long term debt total 0.92M 19.66M 0.56M - -
Other stockholder equity 301.75M 266.01M 255.60M - -
Property plant equipment - - - - -
Total current assets 6.28M 9.38M 6.83M 1.65M 2.44M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.03M 0.82M 0.25M 0.04M 0.09M
Long term debt - 18.72M - 33.40M 23.48M
Inventory 1.55M 1.71M 1.40M 1.29M 1.06M
Accounts payable 2.92M 1.65M 1.55M 1.00M 0.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.12000M -0.12300M -0.11800M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.36M - -0.00000M - -
Deferred long term asset charges - - - - -
Non current assets total 2.28M 2.15M 0.81M 0.91M 0.19M
Capital lease obligations 0.92M 0.94M - 0.69M 0.00000M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.98000M -0.17300M -0.21800M -0.12500M
Change to liabilities - - - - -
Total cashflows from investing activities -0.17900M -0.98000M - - -
Net borrowings 9.17M 19.08M - - -
Total cash from financing activities 16.63M 20.20M 21.84M 8.09M 8.06M
Change to operating activities - - - - -
Net income -23.75600M -22.45200M -29.90800M -15.92300M -8.67500M
Change in cash -1.74400M 1.26M 4.04M -0.93800M 0.99M
Begin period cash flow 5.48M 4.22M 0.18M 1.12M 0.13M
End period cash flow 3.74M 5.48M 4.22M 0.18M 1.12M
Total cash from operating activities -18.20100M -17.94900M -17.65400M -8.80500M -6.93600M
Issuance of capital stock 7.10M 1.75M - - -
Depreciation 0.30M 0.17M 0.13M 0.07M 0.07M
Other cashflows from investing activities - - - - -
Dividends paid 1.82M 2.45M - - -
Change to inventory 0.13M -0.38000M -0.01000M -0.19400M 0.06M
Change to account receivables 0.77M -0.57200M -0.20500M 0.05M -0.01900M
Sale purchase of stock 0.18M 0.06M - - -
Other cashflows from financing activities -0.06200M 0.90M 11.85M 0.09M 8.06M
Change to netincome - - - - -
Capital expenditures 0.18M 0.98M 0.15M 0.22M 0.12M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.84M -0.63800M -0.95800M -0.16000M -0.08200M
Stock based compensation 0.09M 0.56M 1.57M - -
Other non cash items 3.33M 4.97M 13.01M 7.20M 1.75M
Free cash flow -18.38000M -18.92900M -17.80700M -9.02300M -7.06100M

Peer Comparison

Sector: Industry:

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
COCHW
Envoy Medical Inc.
-0.0169 35.58% 0.03 - - - -
DOGEF
Orsted A/S
- -% 22.01 28.82 0.66 6.50 0.07 3.88 15.58
NCRRP
NCR Corp Pref A
- -% 1002.00 1034.35 - - -
TBB
AT&T Inc. 5.35% GLB NTS 66
- -% 20.53 4.60 - - -
CCZ
Comcast Holdings Corp
-0.95 1.45% 64.55 55.07 - - -

Reports Covered

Stock Research & News

Profile

Envoy Medical, Inc., a hearing health company, focuses on providing medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

Envoy Medical Inc.

4875 White Bear Parkway, White Bear Lake, MN, United States, 55110

Key Executives

Name Title Year Born
Mr. Brent T. Lucas Esq. CEO & Director 1983
Mr. David R. Wells Chief Financial Officer 1962
Mr. Brent T. Lucas Esq. CEO & Director 1982
Mr. Robert M. Potashnick Interim CFO & Principal Accounting Officer 1981
Ms. Karin Simonson VP, General Counsel & Corporate Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.